What Bimini Bay LLC does

Hainan Poly Pharmaceutical Co., Ltd. (海南普利制药股份有限公司) is a vertically integrated Chinese pharmaceutical manufacturer founded in 1992 and publicly listed on the Shenzhen Stock Exchange Growth Enterprise Market (ticker 300630) since 2017. The company operates three manufacturing bases — Haikou (Hainan), Hangzhou (Zhejiang), and Anqing (Anhui) — plus an R&D institute in Beijing, collectively spanning over 500 acres with capabilities in injectables, tablets, capsules, granules, dry suspensions, ointments, eye drops, pre-filled syringes, oral liquids, and APIs. Its technology platform includes membrane separation, high-efficiency purification, micronization, high-activity closed isolation systems, spray and lyophilization drying, with cGMP compliance certified by US FDA, EU EMA, WHO, and China NMPA. Beyond conventional generics, Poly operates a synthetic biology platform (CRISPR/Cas-engineered E. coli, yeast, glutamic acid bacteria) producing health product ingredients and an emerging BNCT (Boron Neutron Capture Therapy) drug pipeline developed jointly with the Chinese Academy of Sciences Institute of High Energy Physics.

The company generates revenue through three primary streams: pharmaceutical product sales (APIs and finished dosage forms), contract development and manufacturing services (CDMO/CMO covering CRO, CMO, and CSO functions), and international exports to over 30 countries including the US, Germany, France, Netherlands, UK, Canada, and Australia. Core commercial assets include the Fubeiding (desloratadine) anti-allergy franchise commanding over 80% domestic market share, Sodium Nitroprusside Injection with approximately 56% combined market share across China, US, and Netherlands, and a broad cardiovascular, anti-infective, contrast agent, and CNS portfolio. Distribution combines direct sales to 15,000+ medical institutions in China via 1,000+ distributors with international export channels through regulatory approvals. Notable CDMO partnerships include Imunon Inc. for the manufacture of IMNN-001 immunotherapy for ovarian cancer.

The customer base spans Chinese hospital networks, international generic pharmaceutical markets in regulated jurisdictions, and global pharmaceutical companies seeking contract manufacturing services. Pricing is driven through China's centralized procurement/tender system for domestic sales and contract-based export arrangements internationally, with publicly disclosed pricing not available. The company holds 100+ international marketing approvals, 21 products with 36 FDA marketing approvals, 97 innovation patents (including 80 invention patents), and 260 total product approvals — supporting a multi-jurisdictional generics, specialty injectable, and emerging CDMO/synthetic biology platform business model.

Name

Bimini Bay LLC

Legal name

Hainan Poly Pharmaceutical Co., Ltd. (海南普利制药股份有限公司)

Website

https://biminibaysailing.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

1–10 employees

Short description

Hainan Poly Pharmaceutical is a vertically integrated Chinese generic drug manufacturer (Shenzhen GEM: 300630) producing APIs, injectables, and oral solids across three manufacturing bases, exporting to 30+ countries with FDA/EMA/WHO cGMP certifications and operating a growing CDMO/CMO services business.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Injectable formulations
• Contract drug manufacturing
• Finished dosage forms

Headquarters

HQ city

Haikou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue from manufacturing and selling pharmaceutical products including APIs, injectables, oral solids, eye drops, and other dosage forms to domestic and international markets.
2. CDMO/CMO Services: Contract development and manufacturing services for domestic and foreign customers, providing R&D and production support from clinical approval to commercialization.
3. International Export: Products exported to US, Germany, France, Netherlands, UK, Canada, Australia and other countries through international regulatory approvals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Hainan Poly Pharmaceutical is a vertically integrated pharmaceutical manufacturer that develops, registers, produces and sells Active Pharmaceutical Ingredients (APIs) and finished dosage forms — injectables, tablets, capsules, dry suspensions, granules, eye drops, ointments, pre-filled syringes and oral liquids — across three production bases in Haikou, Hangzhou and Anqing, with lines certified to US FDA, EU EMA, WHO and China NMPA cGMP standards. It also offers one-stop CDMO/CMO services (CRO + CMO + CSO) covering R&D, regulatory registration, manufacturing and overseas sales for domestic and foreign pharmaceutical partners.

Product overview

Poly Pharm (海南普利制药) is a vertically integrated pharmaceutical company offering a comprehensive portfolio of finished pharmaceutical products, Active Pharmaceutical Ingredients (APIs), and contract manufacturing services. The company operates three manufacturing bases (Hainan, Zhejiang, Anhui) and one R&D institute (Beijing) with capabilities spanning injectables, tablets, capsules, granules, dry suspensions, ointments, eye drops, pre-filled syringes, and oral liquids. Core products include the anti-allergy Fubeiding (芙必叮) series with over 80% domestic market share, cardiovascular drugs like Sodium Nitroprusside Injection, anti-infectives like Azithromycin Injection, and contrast agents like Iopamidol. The company provides CDMO/CMO services from R&D through commercialization, including CRO, CMO, and CSO for global markets. Emerging areas include BNCT boron drugs for cancer treatment and synthetic biology products.

Differentiator

Problem solved

Functional benefit

Brands

• 芙必叮 (Fubiding): Desloratadine product series including tablets, dry suspension, oral solution - flagship anti-allergy brand with over 80% domestic market share
• 诺福丁 (Nuofu Ding)
• 普利舒奥
• 闪释 (Shan Shi)
• 普利泮妥
• 普利舒利

Quantifiable outcome

• 地氯雷他定片国内市场占有率超80%
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• Imunon, Inc.coreStrategic or Co-development Partner · 1 November 2024Deep CDMO cooperation with US innovative pharmaceutical company Imunon for developing new immunotherapy drug IMNN-001 for ovarian cancer treatment. Poly provided high-quality clinical batch samples for early clinical trials with excellent results in Phase II trials showing improved overall survival.
• Chinese Academy of Sciences Institute of High Energy Physics (IHEP)coreStrategic or Co-development PartnerJoint establishment of Beijing Poly Biopharm innovation drug R&D platform focusing on BNCT (Boron Neutron Capture Therapy) drugs and new targeted boron drugs. Cooperation with core advantages in BNCT technology.
• Zhejiang UniversitymajorStrategic or Co-development PartnerStrong partnerships established for BNCT new boron carrier development, combining drug design, pharmacology and toxicology research, and CMC expertise.
• Zhejiang Roly Pharm (瑞利药业)coreChannel Partner/ Reseller/ DistributorWholly-owned subsidiary sales company covering domestic marketing with network over 15,000 medical institutions, 5,000+ secondary and above hospitals, 10,000+ primary healthcare institutions.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

Broad incumbents

• Lupin Limited: Indian-headquartered generic pharma with strong US injectable franchise and FDA-inspected manufacturing. Comparable on generic injectable launches in the US market and complex formulation capabilities.
• Aurobindo Pharma: Large Indian generic manufacturer with extensive FDA approvals and vertically integrated API manufacturing across injectables and orals. Closely comparable on regulated-market generic injectables + API integration strategy.
• Shanghai Fosun Pharmaceutical: Diversified Chinese pharma conglomerate with API, finished formulation, CDMO, and international expansion across regulated markets. Comparable on the breadth of capabilities (API + formulations + CDMO + overseas approvals), but with a much larger portfolio and biosimilar exposure.
• Dr. Reddy's Laboratories: India-headquartered global generic and CDMO player with deep US FDA inspection track record and integrated API-to-formulations model. Comparable on vertically-integrated generics + CDMO + complex injectables (including oncology) targeting regulated markets.
• CSPC Pharmaceutical Group: Large Hong Kong-listed Chinese pharma with significant API and finished-product manufacturing, including injectables, and a sizable CDMO operation. Comparable on integrated pharma manufacturing with international ambitions, though substantially larger and more diversified than Poly.
• Shanghai Pharmaceuticals Holding: State-owned Chinese pharmaceutical manufacturer and distributor with API and finished formulation businesses plus domestic hospital distribution. Comparable on domestic hospital channel and integrated manufacturing, though more distribution-heavy than Poly.
• Jiangsu Hengrui Medicine: China's largest innovative pharma with growing international injectable and biosimilar business targeting FDA approvals. Comparable on Chinese-pharma-with-regulated-market-ambitions positioning, though primarily innovation-led rather than CDMO/generic.

Direct peers

• Zhejiang Huahai Pharmaceutical: Leading Chinese API manufacturer with significant US FDA and EU EMA approvals for finished formulations, including generic cardiovascular and CNS products overlapping with Poly's portfolio. Closely comparable on international regulated-market generics strategy.
• Apeloa Pharmaceutical: Chinese vertically-integrated API-to-finished-product manufacturer with international (FDA/EMA) approvals and a CDMO business model structurally similar to Poly's. Directly comparable on integrated CDMO/CMO positioning targeting both domestic and US/EU markets.
• Zhejiang Hisun Pharmaceutical: Chinese API and finished formulation manufacturer with FDA/EMA approvals and growing international CDMO business. Comparable on integrated API + finished product + overseas regulated markets strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bimini-bay-llc

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bimini Bay LLC